Neurophysiological and Acute Pharmacological Studies in FXS Patients
Status:
Completed
Trial end date:
2020-11-01
Target enrollment:
Participant gender:
Summary
The aim of this study is to utilize neurophysiologic assessments, behavioral measures and
clinical measures to assess how much deficits associated with Fragile X Syndrome from
pre-dose to post-dose using pharmacology.
Phase:
Early Phase 1
Details
Lead Sponsor:
Children's Hospital Medical Center, Cincinnati
Collaborator:
Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)
Treatments:
Acamprosate Baclofen Dihydromevinolin L 647318 Lovastatin Minocycline